вот такое с этой статьи:
7.2.1.3. Ongoing pregnancies. After more than 10 years of
mifepristone use in several European countries, a few case
reports of normal pregnancies and offspring have been recorded
when women have taken mifepristone alone or in
combination with a prostaglandin; these women had not
aborted and had elected to continue their pregnancies [51].
Only one anomaly was reported after the use of mifepristone
alone. This case, described as sirenomelia [52], could
not be related to the drug intake. Indeed, the type of anomaly
observed occurred at a very early stage of pregnancy,
about 4 weeks of embryo development, while the treatment
was taken at the 5th week of pregnancy. Seven other cases
of malformations were reported, and all occurred in pregnancies
of 7–9 weeks of amenorrhea and when gemeprost
was administered after mifepristone. None of the described
events could be related to the combination of treatment.
Given the known incidence of birth defects in a normal
population, around 2.5% per year in the European registry,
it is not possible to determine whether the reported anomalies
were coincidental or not. Some prostaglandins have
been classified as teratogenic, however, misoprostol did not
induce such effects in embryotoxicology studies. Although
mifepristone is not a teratogenic agent, its effect on uterine
contractility, when used in combination with a prostaglandin,
may induce uterine retraction accounting for some of
the observed defects [12]. For other indications in which the
drug is administered in much lower doses and not during
embryo development, there is no reason to believe that such
risk would exist.
Pharmacological properties of mifepristone: toxicology and safety in animal and human studies
[Ссылки доступны только зарегистрированным пользователям ]
|